Best Albuminuria Drug for Diabetes Varies by Patient
Multiple guidelines recommend a RAS inhibitor (ACE-I or ARBs) as the first-line agent to treat patients with diabetes with micro- or macroalbuminuria. A controlled study of 63 people with diabetes showed that in nearly half an agent from a different drug class outperformed an ARB for bringing down albuminuria. Treatment with the ARB telmisartan ran true to form and performed best in 33 patients (52%). But notably, the other 30 patients — nearly half — had their best albuminuria-lowering response to one of the other three drugs. Eleven patients (17%) had their most robust albumin reduction with empagliflozin, another 11 fared best with linagliptin, and eight participants (13%) had their largest drop in albuminuria with baricitinib.